UF-021 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 90 | 網膜色素変性症 | 3 |
90. 網膜色素変性症
臨床試験数 : 130 / 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01786395 (ClinicalTrials.gov) | March 2013 | 23/1/2013 | Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa | Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Retinitis Pigmentosa | Drug: UF-021;Drug: Placebo | R-Tech Ueno, Ltd. | NULL | Terminated | 20 Years | 70 Years | Both | 202 | Phase 3 | Japan |
| 2 | JPRN-JapicCTI-090748 | 01/10/2008 | 20/04/2009 | Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa | Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa | retinitis pigmentosa | Intervention name : UF-021 (isopropyl unoprostone) Dosage And administration of the intervention : Eye drop | R-Tech Ueno, Ltd | NULL | 20 | 65 | BOTH | 105 | Phase 2 | NULL | |
| 3 | JPRN-JapicCTI-132079 | Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Retinitis Pigmentosa | Intervention name : UF-021(isopropyl unoprostone) Dosage And administration of the intervention : Eye drop Control intervention name : null | R-Tech Ueno, Ltd | NULL | 20 | 70 | BOTH | Phase 3 | NULL |